| Literature DB >> 34948899 |
Ziyad Tariq Muhseen1,2, Mustafa Hussein Ali3, Nawar Rushdi Jaber4, Dheyaa Shakir Mashrea5, Ali Mamoon Alfalki6, Guanglin Li1,2.
Abstract
The 8-oxoguanine DNA glycosylase (OGG1) enzyme is a key DNA glycosylase mediating the excision of 7,8-dihydro-8-oxoguanine (8-oxoG) from DNA molecule to the start base excision repair pathway. The OGG1 glycosylase function depletion has been seen to obstruct pathological conditions such as inflammation, A3 T-cell lymphoblastic acute leukemia growth, and neurodegenerative diseases, thus warranting OGG1 as an attractive anti-cancer enzyme. Herein, we employed several drug libraries intending to screen non-toxic inhibitory molecules against the active pocket of the enzyme that achieved stable binding mode in dynamics. Two anti-cancer compounds ([O-]C1=C(CC2=CC=CC=C2)SC(=[N+]1CC(=O)NC3=NC=C(CC4=CC=CC=C4)S3)S and CCCN(CCC)[S]-(=O)(=O)C1=CC=C(C=C1)C(=O)NNC2=NC3=CC=C(Br)C=C3C(=N2)C4=CC=CC=C4) from Selleckchem.com were identified to occupy the active pocket of OGG1 and bind with greater affinity than Control TH5487. The binding affinity of Top-1 is -11.6 kcal/mol while that of Top-2 is -10.7 kcal/mol in contrast to TH5487 Control (-9 kcal/mol). During molecular dynamic simulations versus time, the said compounds are tightly held by the enzyme with no minor structural deviations reported except flexible loops in particular those present at the N and C-terminal. Both the compounds produced extensive hydrophobic interactions with the enzyme along with stable hydrogen bonding. The docking and molecular dynamics simulations predictions were further validated by molecular mechanics with generalized Born and surface area solvation (MM/GBSA) and Poisson Boltzmann surface area (MM/PBSA), and WaterSwap binding energies that validated strong binding of the compounds to the enzyme. The MM/GBSA binding free energy for Top-1 complex is -28.10 kcal/mol, Top-2 complex is -50.14 kcal/mol) and Control is -46.91 kcal/mol while MM/PBSA value for Top-1, Top-2 and Control is -23.38 kcal/mol, -35.29 kcal/mol and -38.20 kcal/mol, respectively. Computational pharmacokinetics support good druglike candidacy of the compounds with acceptable profile of pharmacokinetics and very little toxicity. All these findings support the notion that the compounds can be used in experiments to test their anti-cancer activities.Entities:
Keywords: MD simulations; TH5487; base excision repair; binding free energies; glycosylase inhibitor; molecular docking
Mesh:
Substances:
Year: 2021 PMID: 34948899 PMCID: PMC8706639 DOI: 10.3390/ijerph182413290
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Virtually screened compounds and their docking scores.
| Compound | GOLD Score | Autodock Vina Binding Free Energy (kcal/mol) | ASP | CHEMPLP | Chem Score |
|---|---|---|---|---|---|
|
| 79 | −11.6 | 18.71 | 56.88 | 17.84 |
|
| 76 | −10.7 | 16.10 | 54.89 | 16.20 |
|
| 72 | −9.0 | 16.30 | 51.9 | 14.84 |
|
| 74 | −9.8 | 17.37 | 50.74 | 15.87 |
|
| O8 | −11.54 | 19.57 | 53.97 | 17.52 |
Figure 1Molecular docking analysis of Control and shortlisted best binders. Both intermolecular docking conformation and interactions are provided. (A) 3D conformation of Control (shown in cyan stick), (B) Top-1 (shown in yellow stick), and (C) Top-2 (shown in green stick) at the active pocket of OGG1 enzyme (shown in secondary structure ribbon), and 2D presentation of enzyme residues interaction with the compounds.
Figure 2Molecular dynamic simulation analysis. All provided analysis are done based on carbon alpha atoms. The structural dynamics of complexes are given as a function of time. (A) RMSD, (B) RMSF, (C) Rg, and (D) B-factor.
Figure 3Hydrogen bonds analysis in each frame of simulation time. The bar figure provides number of hydrogen bonds established between the compounds and enzyme during simulation time.
Figure 4Radial distribution analysis of hydrogen bonds/van der Waals formed between the compounds and enzyme active site residues. (A) Control, (B) Top-1, and (C) Top-2. Only key interactions are plotted in radial distribution analysis.
MM/GBSA and MM/PBSA binding free energy estimated from 500 frames of molecular dynamics simulation. The net binding free energy value is decomposed further into respective electrostatic, van der Waals, polar, and non-polar solvation energies.
| MM/GBSA | |||||||
|---|---|---|---|---|---|---|---|
| Compound | ΔG Binding (kcal/mol) | ΔG Electrostatic (kcal/mol) | ΔG Bind van der Waals (kcal/mol) | ΔG Gas Phase (kcal/mol) | ΔG Polar Solvation (kcal/mol) | ΔG Non-Polar Solvation (kcal/mol) | ΔG Solvation (kcal/mol) |
|
| −28.10 | −25.26 | −41.42 | −66.69 | 44.40 | −5.80 | 38.59 |
|
| −50.14 | −17.00 | −60.47 | −77.47 | 34.54 | −7.21 | 27.32 |
|
| −46.91 | −23.10 | −56.70 | −79.81 | 38.54 | −5.64 | 32.90 |
|
| |||||||
|
| −23.38 | −25.26 | −41.42 | −66.69 | 47.85 | −4.54 | 43.30 |
|
| −35.29 | −17.00 | −60.47 | −77.47 | 47.50 | −5.32 | 42.17 |
|
| −38.20 | −23.10 | −56.70 | −79.81 | 45.55 | −3.94 | 41.60 |
Net binding energy value of compounds and their interacting residues that are highly stable in complex formation in simulation time. The energy values are given in kcal/mol. Moreover, alanine scanning results when key compounds interacting residues are mutated to alanine. NA (not applicable).
| Ligand/Residue | Top-1 | Alanine Scanning Results | Top-2 | Alanine Scanning Results |
|---|---|---|---|---|
| Ligand | −15.06 | NA | −24.28 | NA |
| Ile142 | −3.209 | −2.14 | −4.38 | −2.80 |
| Phe134 | −1.90 | −1.20 | −2.74 | −1.11 |
| Phe306 | −1.77 | −0.98 | −2.84 | −1.44 |
| Ala143 | −1.19 | −1.0 | −1.75 | −1.12 |
| Cys243 | −0.97 | NA | −1.55 | NA |
| Gln33 | −0.82 | NA | −1.50 | NA |
| Ile145 | −0.80 | NA | −1.35 | NA |
| Met247 | −0.71 | NA | −1.28 | NA |
| His260 | −0.47 | 1.0 | −1.10 | −1.00 |
| Leu122 | −0.45 | NA | −0.87 | NA |
| Ala303 | −0.41 | NA | −0.80 | NA |
| Leu246 | −0.39 | NA | −0.73 | NA |
| Gly32 | −0.35 | −1.04 | −0.70 | −1.10 |
| Pro256 | −0.33 | −1.0 | −0.61 | −1.01 |
| Leu310 | −0.25 | NA | −0.55 | NA |
| Phe35 | −0.22 | 0.12 | −0.54 | −0.41 |
| Val240 | −0.21 | NA | −0.50 | NA |
| Ser31 | −0.21 | 0.11 | −0.48 | 1.18 |
Figure 5WaterSwap binding free energies are estimated by different methods such TI, FEP, and BENNETTS. The energy values are given in kcal/mol.
Computational pharmacokinetics along with several pharmaceutically important parameters of the compounds.
| Property | Compounds | ||
|---|---|---|---|
| Physicochemical Properties | Top-1 | Top-2 | Control |
| Formula | C22H19N3O2S3 | C27H28BrN5O3S | C19H19BrIN4O2 |
| Molecular weight | 453.60 g/mol | 582.51 g/mol | 542.19 g/mol |
| Num. heavy atoms | 30 | 37 | 27 |
| Num. arom. heavy atoms | 22 | 22 | 11 |
| Fraction Csp3 | 0.14 | 0.22 | 0.32 |
| Num. rotatable bonds | 8 | 11 | 4 |
| Num. H-bond acceptors | 3 | 6 | 2 |
| Num. H-bond donors | 1 | 2 | 2 |
| Molar Refractivity | 123.71 | 149.71 | 118.21 |
| TPSA | 164.21 Å2 | 112.67 Å2 | 70.77 Å2 |
| Lipophilicity | |||
| Consensus Log Po/w | 4.22 | 5.00 | 2.38 |
| Water Solubility | Moderately soluble | Moderately soluble | Moderately soluble |
| Pharmacokinetics | |||
| GI absorption | High | High | High |
| BBB permeant | No | No | Yes |
| P-gp substrate | No | No | Yes |
| CYP1A2 inhibitor | No | No | No |
| CYP2C19 inhibitor | Yes | Yes | No |
| CYP2C9 inhibitor | Yes | Yes | No |
| CYP2D6 inhibitor | No | No | No |
| CYP3A4 inhibitor | No | No | No |
| Log Kp (skin permeation) | −4.93 cm/s | −4.80 cm/s | −7.34 cm/s |
| Druglikensess | |||
| Lipinski | Yes; 0 violation | Yes; 1 violation: MW > 500 | Yes; 1 violation: MW > 500 |
| Medicinal Chemistry | |||
| PAINS | 0 alert | 0 alert | 1 alert acyl_het_A |
| Synthetic accessibility | 3.86 | 3.72 | 4.76 |
| Toxicity | |||
| Hepatotoxicity | No | Yes | Yes |
| Skin sensitisation | No | No | No |
| T. pyriformis toxicity | 0.292 log ug/L | 0.285 log ug/L | 0.315 log ug/L |
| Ames toxicity | No | No | No |
| Minnow toxicity | 0.69 log mM | −1.164 log mM | −1.14 log mM |
| Carcino mouse | No | No | No |
| Excretion | |||
| Total clearance | 0.763 log mL/min/kg | 0.026 log mL/min/kg | 0.031 log mL/min/kg |
| Renal OCT2 substrate | No | No | No |